Research Fellowship at Center for Accelerating Leukemia/Lymphoma Research

Job Title: Research Fellowship at Center for Accelerating Leukemia/Lymphoma Research 

One pre-doctoral position is available at CALR (https://www.humanitas.eu/calr/), Humanitas University to elucidate cellular and molecular pathways linking clonal hematopoiesis and chronic inflammation in myeloid neoplasms and related pre-clinical disorders.

The project will take place within the frame of an international collaborative research project supported by Italian Agency for Cancer Research (AIRC) - PI Dott. Gabriele Todisco.
We are looking for a curious, motivated, and passionate junior scientist with experience in molecular biology techniques. You must be a good team player but still retain enough independence to explore your results from a conceptual standpoint.
 

Responsabilities
The ideal candidate would have a degree in Biotechnology, Biological sciences, Genetics, or related disciplines and preferably 1-2 years laboratory training in molecular biology. The successful candidate will be responsible for preparing samples for Next Generation Sequencing (NGS) experiments, including extraction, quantification, and quality assessment of nucleic acids from bone marrow or peripheral blood. Methods will involve DNA and RNA sequencing, single-cell sequencing, cell culture systems, advanced flow cytometry and sorting.
 

Requirements
· Excellent team-working capabilities even with colleagues from different research areas and international backgrounds; 
· Strong self-motivation, commitment and proactive approach;
· Ability to meet deadlines and work autonomously in rapidly changing environments;
· Curiosity and ability of stepping outside your comfort zone.

The candidate will join a growing and stimulating research environment at the interface between the clinics and the lab, in a research institute of excellence. To apply, please send your CV and a cover letter highlighting your relevant experience.
 

Selected References
· Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts. Todisco G et al, Clin Cancer Res. 2023 Oct 13;29(20):4256-4267.
· Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Todisco G et al, Leukemia. 2021 Aug;35(8):2371-2381. 
· Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome. Guzzi N et al, Nat Cell Biol. 2022 Mar;24(3):299-306.
· ZBTB33 is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing. Beauchamp EM et al, Blood Cancer Discov. 2021 Sep;2(5):500-517